Answer
Avoid Tzield (teplizumab) during pregnancy and for at least 30 days before a planned pregnancy to minimise foetal exposure, as it may cause immunosuppression in the exposed infant and available pregnancy reports are insufficient to establish drug-associated risks.
Sources for this answer
- Tzield 2 mg/2 mL concentrate for solution for infusionSANOFI · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 3Document updated
Sources checked